Overview
The study aims to retrospectively collect long-term survival data from patients who received first-line tislelizumab combined with chemotherapy in the RATIONALE-307 trial, in order to enrich the evidence on long-term benefits in advanced squamous NSCLC patients from immunotherapy and to identify patients deriving greater clinical advantage.
Eligibility
Inclusion Criteria:
- Patients with squamous NSCLC who participated in the RATIONALE-307 trial and had no documented death before study completion
Exclusion Criteria:
- Patients who had a documented death before study completion in the RATIONALE-307 trial


